Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO – Get Free Report) gapped down prior to trading on Tuesday after HC Wainwright lowered their price target on the stock from $54.00 to $52.00. The stock had previously closed at $40.06, but opened at $35.80. HC Wainwright currently has a buy rating on the stock. Agios Pharmaceuticals shares last traded at $39.1180, with a volume of 575,336 shares trading hands.
A number of other equities research analysts have also commented on AGIO. The Goldman Sachs Group upped their target price on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Royal Bank Of Canada raised their price target on shares of Agios Pharmaceuticals from $28.00 to $32.00 and gave the stock a “sector perform” rating in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, June 24th. Bank of America lifted their price objective on shares of Agios Pharmaceuticals from $40.00 to $46.00 and gave the company a “buy” rating in a research note on Tuesday, July 7th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of Agios Pharmaceuticals from $36.00 to $31.00 and set a “neutral” rating on the stock in a report on Thursday, June 11th. Six analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $42.78.
Check Out Our Latest Report on AGIO
Key Agios Pharmaceuticals News
- Negative Sentiment: Agios scrapped the tebapivat sickle cell disease program after Phase 2 data failed to show a compelling benefit versus existing options, a setback that weakens a key pipeline opportunity. Article Title
- Negative Sentiment: Multiple reports highlighted the stock’s decline following the decision, with coverage emphasizing that the company is abandoning the sickle cell candidate after lackluster trial results. Article Title
- Negative Sentiment: Investor sentiment is also being dampened by the loss of a potential growth driver in sickle cell disease, even though Agios’ other PK activator, mitapivat, remains under FDA Priority Review with a PDUFA date of November 1, 2026. Article Title
Institutional Inflows and Outflows
Several institutional investors have recently bought and sold shares of AGIO. Bellevue Group AG boosted its position in Agios Pharmaceuticals by 3.5% in the 3rd quarter. Bellevue Group AG now owns 3,714,736 shares of the biopharmaceutical company’s stock worth $149,110,000 after purchasing an additional 124,586 shares in the last quarter. State Street Corp increased its holdings in shares of Agios Pharmaceuticals by 37.4% during the 4th quarter. State Street Corp now owns 3,108,145 shares of the biopharmaceutical company’s stock valued at $84,604,000 after purchasing an additional 845,433 shares in the last quarter. Erste Asset Management GmbH increased its holdings in shares of Agios Pharmaceuticals by 1.4% during the 4th quarter. Erste Asset Management GmbH now owns 2,804,900 shares of the biopharmaceutical company’s stock valued at $76,343,000 after purchasing an additional 40,000 shares in the last quarter. Wellington Management Group LLP lifted its stake in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after purchasing an additional 2,049,287 shares during the period. Finally, Commodore Capital LP lifted its stake in shares of Agios Pharmaceuticals by 6.4% in the 2nd quarter. Commodore Capital LP now owns 2,325,000 shares of the biopharmaceutical company’s stock valued at $77,330,000 after purchasing an additional 140,000 shares during the period.
Agios Pharmaceuticals Price Performance
The stock’s fifty day moving average is $33.58 and its 200-day moving average is $30.56. The stock has a market capitalization of $2.14 billion, a PE ratio of -4.97 and a beta of 0.54.
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) EPS for the quarter, beating the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative net margin of 639.84% and a negative return on equity of 34.11%. The company had revenue of $20.75 million for the quarter, compared to analyst estimates of $13.30 million. The company’s quarterly revenue was up 137.7% on a year-over-year basis. On average, analysts forecast that Agios Pharmaceuticals, Inc. will post -6.32 EPS for the current year.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.
Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.
Read More
- Five stocks we like better than Agios Pharmaceuticals
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
